{"organizations": [], "uuid": "b3891593d9d5504e924addb8ca3e72ec9002045f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-co-says-keytruda-phase-3-key/brief-merck-co-says-keytruda-phase-3-keynote-189-trial-met-its-dual-primary-endpoints-idUSFWN1PB0LH", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.995, "site_type": "news", "published": "2018-01-16T20:35:00.000+02:00", "replies_count": 0, "uuid": "b3891593d9d5504e924addb8ca3e72ec9002045f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-co-says-keytruda-phase-3-key/brief-merck-co-says-keytruda-phase-3-keynote-189-trial-met-its-dual-primary-endpoints-idUSFWN1PB0LH", "ord_in_thread": 0, "title": "BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-merck & co says keytruda phase", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Merck & Co Inc:\n* MERCK‘S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189)\n* MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-189 TRIAL MET ITS DUAL PRIMARY ENDPOINTS\n* MERCK & CO INC - ‍SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T20:35:00.000+02:00", "crawled": "2018-01-17T19:46:48.029+02:00", "highlightTitle": ""}